ISSN: 0034-8376
eISSN: 2564-8896






Circulating MicroRNA-30e Predicts Left Ventricular Hypertrophy In Essential Hypertensive Patients



Haiying Xu, Department of Cardiology, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang and Hangzhou First People's Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Yizhou Xu, Department of Cardiology, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang and Hangzhou First People's Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Jun Yang, Department of Cardiology, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang and Hangzhou First People's Hospital of Zhejiang University, Hangzhou, Zhejiang, China
Jinyu Huang, Department of Cardiology, The Fourth Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang and Hangzhou First People's Hospital of Zhejiang University, Hangzhou, Zhejiang, China


Background: The biomarker for left ventricular hypertrophy (LVH) in patients with essential hypertension (EH) remains an unmet clinical need. The microRNA-30 (miR-30) family has been associated with LVH in cellular and animal studies, but not in a clinical setting. Objective: The objective of the study was to investigate the clinical significance of circulating levels of miR-30 family as a biomarker for LVH in EH patients. Methods: A total of 239 EH patients and 239 healthy controls were enrolled in this study. Circulating levels of miR-30 family members, namely, miR-30a, miR-30b, miR-30c-1, miR-30c-2, miR- 30d, and miR-30e, were evaluated using real-time polymerase chain reaction assays. Results: The circulating miR-30a, miR-30b, and miR-30e were significantly reduced in EH patients in contrast to controls. EH patients with LVH (EH-LVH) had substantially lower circulating miR-30b and miR-30e levels compared to EH patients without LVH (EH-nLVH). Moreover, the expression levels of miR-30b and miR-30e were positively related to LVMI, respectively. Receiver operating curve analysis showed that circulating miR-30e levels distinguished EH patients from controls, and EH-LVH from EH-nLVH patients. Logistic regression analysis identified the circulating miR-30e as a risk factor for LVH in EH patients. Conclusion: Circulating miR-30e level can be used as a biomarker in distinguishing EH-LVH from EH-nLVH. A further prospective study is warranted to validate this finding.



Keywords: Essential hypertension. Left ventricular hypertrophy. MicroRNA.